Halozyme Therapeutics, Inc. (HALO)

Market Cap	7.28B
Revenue (ttm)	1.08B
Net Income (ttm)	485.36M
Shares Out	123.22M
EPS (ttm)	3.76
PE Ratio	15.71
Forward PE	10.25
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,472,111
Open	57.75
Previous Close	57.73
Day's Range	57.68 - 59.49
52-Week Range	42.01 - 70.51
Beta	1.15
Analysts	Buy
Price Target	65.63 (+11.14%)
Earnings Date	Aug 5, 2025

About HALO

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the disper...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 350
• Stock Exchange: NASDAQ
• Ticker Symbol: HALO
• Website: https://halozyme.com

Financial Performance

In 2024, Halozyme Therapeutics's revenue was $1.02 billion, an increase of 22.44% compared to the previous year's $829.25 million. Earnings were $444.09 million, an increase of 57.71%.

Analyst Summary

According to 8 analysts, the average rating for HALO stock is "Buy." The 12-month stock price target is $65.63, which is an increase of 11.14% from the latest price.

Price Target

$65.63

(11.14% upside)

Analyst Consensus: Buy